Systemic inflammatory cytokines and immune cells

Systemic inflammatory cytokines and immune cells refer to the integrated network of signaling molecules and cellular effectors that mediate the body's inflammatory response. This system includes key pro-inflammatory cytokines such as Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 (IL-1), and Interleukin-6 (IL-6), which are primarily produced by activated macrophages and helper T-cells (StatPearls, 2023). Under normal conditions, these components facilitate host defense against pathogens and promote tissue repair; however, their systemic dysregulation is a hallmark of conditions like sepsis, cytokine release syndrome (CRS), and various autoimmune disorders (PubMed, 2021). Therapeutic strategies do not target the entire system at once but rather focus on specific nodes, such as using monoclonal antibodies to neutralize individual cytokines or small molecules to inhibit downstream signaling pathways like JAK/STAT (NIH, 2022). Because this term describes a broad physiological category involving hundreds of distinct molecular entities and cell types, it is not considered a single discrete therapeutic target. Instead, it serves as a conceptual framework for understanding the pathophysiology of systemic inflammation and the multi-target approach often required in clinical immunology.

Other names

Pro-inflammatory mediatorsSystemic inflammatory response systemImmune system componentsInflammatory secretome

Inhibition of cytokine signaling, neutralization of soluble mediators, and modulation of immune cell activation and recruitment.